Ending Chemical Abortions Act of 2025
- Bill Number
- H.R. 629
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Crime and Law Enforcement
- Status
- Introduced
- Latest Action
- 2025-01-22: Referred to the House Committee on the Judiciary.
- Last Updated
- 2026-06-11T08:06:45Z
AI-Generated Summary
Purpose of the Legislation
The "Ending Chemical Abortions Act of 2025" aims to ban the use of drugs, medications, or chemicals specifically for inducing abortions (known as chemical abortions) at the federal level. It seeks to address perceived issues with the approval and distribution of such drugs by the Food and Drug Administration (FDA), emphasizing higher complication risks compared to surgical abortions and their growing prevalence.
Key Provisions
- Prohibition on Chemical Abortions: Adds a new section (1532) to Chapter 74 of Title 18, United States Code (which covers federal crimes). This makes it illegal to prescribe, dispense, distribute, or sell any drug intended to terminate a known pregnancy. Penalties include up to 25 years in prison, fines, or both.
- Exceptions:
- Use of contraceptives before pregnancy is confirmed.
- Treatment of a miscarriage following accepted medical guidelines.
- Cases where a woman's life is in danger due to a physical condition related to the pregnancy, as certified by a physician.
- Protections: Women who receive or attempt chemical abortions cannot be criminally prosecuted under this law.
- Definitions:
- Abortion: Intentional ending of a known pregnancy, excluding actions to produce a live birth, remove a miscarried fetus, or treat an ectopic (implantation outside the uterus) or molar (abnormal tissue growth) pregnancy.
- Pregnancy: The condition of carrying a living unborn child from fertilization through birth.
- Unborn child: A human organism from fertilization until live birth.
- Structural Changes: Renames Chapter 74 to "Abortion crimes" and updates the table of contents accordingly.
Significant Changes to Existing Law
- Builds on the existing federal ban on partial-birth abortions (18 U.S.C. § 1531) by adding a specific prohibition on chemical methods, which were not previously covered under this chapter.
- Overrides certain FDA regulations by criminalizing actions like mailing abortion drugs, which the FDA allowed in 2021, and reverses expansions in access (e.g., fewer doctor visits, longer gestational limits).
- Introduces federal criminal penalties for what was previously regulated mainly through FDA oversight and state laws, shifting enforcement to the Department of Justice.
Potential Impacts
- On Government Agencies: The FDA's authority over abortion drug approvals (e.g., mifepristone and misoprostol) could be undermined, leading to legal conflicts or revised drug policies. The Department of Justice would handle prosecutions, potentially increasing federal court caseloads.
- On Citizens: Women seeking non-surgical abortions (over 50% of U.S. abortions per the bill's findings) may face barriers to safe options, increasing reliance on surgical methods or travel. Providers and pharmacists risk severe penalties, deterring services.
- On International Relations: Minimal direct impact, but could affect U.S. pharmaceutical trade or aid policies involving reproductive health drugs, potentially straining relations with countries or organizations promoting global access to abortion medications.
Main Stakeholders Affected
- Healthcare Providers and Pharmacists: Face criminal liability for prescribing or dispensing abortion drugs, except in specified cases.
- Pharmaceutical Companies: Restricted from producing, selling, or distributing drugs like mifepristone for abortion use, impacting revenue from these products.
- Women and Patients: Limited access to chemical abortion options, particularly in areas with few surgical facilities; protections prevent their prosecution but do not address health or travel burdens.
- Anti-Abortion Advocates: Likely supported, as the bill aligns with efforts to restrict abortion access post-2022 Supreme Court decision in Dobbs v. Jackson Women's Health Organization.
- Pro-Choice Groups and Medical Associations: Opposed, due to potential health risks from unregulated alternatives and conflicts with medical standards.
Notable Legal, Constitutional, or Political Implications
- Legal: Likely to face challenges under the Commerce Clause (questioning federal authority over medical practices traditionally left to states) and due process (e.g., vagueness in definitions or exceptions). Conflicts with state laws allowing or protecting abortion access post-Dobbs, creating a patchwork of enforcement.
- Constitutional: References to "unborn child" from fertilization echo fetal personhood debates, potentially influencing broader challenges to Roe v. Wade's legacy or future privacy rights cases. The life-endangerment exception mirrors standards in some state laws but may invite litigation over "certification" by physicians.
- Political: Introduced by Republican representatives, it reflects ongoing partisan divides on abortion. If passed, it could energize national debates, especially amid FDA litigation over mifepristone, and set precedent for further federal restrictions on reproductive rights.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (21)
Rep. Miller, Mary E. [R-IL-15], Rep. Kelly, Trent [R-MS-1], Rep. Bost, Mike [R-IL-12], Rep. Cline, Ben [R-VA-6], Rep. Brecheen, Josh [R-OK-2], Rep. Allen, Rick W. [R-GA-12], Rep. Weber, Randy K. Sr. [R-TX-14], Rep. Crenshaw, Dan [R-TX-2], Rep. Crane, Elijah [R-AZ-2], Rep. Green, Mark E. [R-TN-7], Rep. Clyde, Andrew S. [R-GA-9], Rep. Biggs, Andy [R-AZ-5], Rep. LaMalfa, Doug [R-CA-1], Rep. Gosar, Paul A. [R-AZ-9], Rep. Moore, Barry [R-AL-1], Rep. Boebert, Lauren [R-CO-4], Rep. Grothman, Glenn [R-WI-6], Rep. Ezell, Mike [R-MS-4], Rep. Harris, Andy [R-MD-1], Rep. Biggs, Sheri [R-SC-3], Rep. Burlison, Eric [R-MO-7]
Recent Actions
- 2025-01-22: Referred to the House Committee on the Judiciary.
- 2025-01-22: Introduced in House
- 2025-01-22: Introduced in House
Bill Versions
- Ending Chemical Abortions Act of 2025 — issued 2025-01-22 — PDF (5 pages)